News articles about Heska Corporation (NASDAQ:HSKA) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Heska Corporation earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 46.4874923816334 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Heska Corporation (NASDAQ:HSKA) traded down 0.81% on Friday, hitting $97.79. The stock had a trading volume of 46,232 shares. The firm has a market cap of $706.63 million, a P/E ratio of 49.84 and a beta of 0.82. The firm’s 50-day moving average price is $101.39 and its 200 day moving average price is $96.52. Heska Corporation has a 12 month low of $46.51 and a 12 month high of $115.00.
Heska Corporation (NASDAQ:HSKA) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.07. Heska Corporation had a net margin of 10.70% and a return on equity of 15.87%. The company had revenue of $34.30 million during the quarter, compared to analysts’ expectations of $33.35 million. During the same quarter in the prior year, the company earned $0.35 EPS. Heska Corporation’s revenue was up 14.3% compared to the same quarter last year. Analysts anticipate that Heska Corporation will post $2.04 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Heska Corporation (HSKA) Earning Somewhat Favorable Media Coverage, Report Shows” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.com-unik.info/2017/08/19/heska-corporation-hska-getting-somewhat-positive-press-coverage-report-finds-updated-updated.html.
In other Heska Corporation news, CFO John Mcmahon sold 587 shares of the business’s stock in a transaction dated Tuesday, May 23rd. The shares were sold at an average price of $97.00, for a total value of $56,939.00. Following the transaction, the chief financial officer now directly owns 295 shares in the company, valued at approximately $28,615. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Nancy Wisnewski sold 250 shares of the business’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $100.17, for a total transaction of $25,042.50. Following the completion of the transaction, the executive vice president now owns 38,901 shares in the company, valued at $3,896,713.17. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,265 shares of company stock valued at $2,983,439. 14.70% of the stock is owned by corporate insiders.
Heska Corporation Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
What are top analysts saying about Heska Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Heska Corporation and related companies.